Natixis Advisors’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $375M | Buy |
1,978,508
+666,009
| +51% | +$125M | 0.42% | 43 |
|
|
2026
Q1 | $259M | Buy |
1,312,499
+285,743
| +28% | +$55.1M | 0.36% | 62 |
|
|
2025
Q4 | $189M | Sell |
1,026,756
-23,439
| -2% | -$4.11M | 0.27% | 84 |
|
|
2025
Q3 | $161M | Buy |
1,050,195
+131,232
| +14% | +$19.9M | 0.24% | 90 |
|
|
2025
Q2 | $128M | Sell |
918,963
-199,043
| -18% | -$27.9M | 0.2% | 112 |
|
|
2025
Q1 | $164M | Buy |
1,118,006
+87,907
| +9% | +$12.7M | 0.3% | 70 |
|
|
2024
Q4 | $135M | Buy |
1,030,099
+49,691
| +5% | +$6.96M | 0.25% | 77 |
|
|
2024
Q3 | $153M | Buy |
980,408
+58,581
| +6% | +$9.46M | 0.3% | 66 |
|
|
2024
Q2 | $144M | Buy |
921,827
+138,973
| +18% | +$20.9M | 0.31% | 66 |
|
|
2024
Q1 | $106M | Buy |
782,854
+157,545
| +25% | +$20.9M | 0.24% | 95 |
|
|
2023
Q4 | $84.2M | Buy |
625,309
+39,143
| +7% | +$5.09M | 0.22% | 106 |
|
|
2023
Q3 | $79.4M | Buy |
586,166
+18,834
| +3% | +$2.57M | 0.24% | 97 |
|
|
2023
Q2 | $81.2M | Buy |
567,332
+66,132
| +13% | +$9.73M | 0.25% | 98 |
|
|
2023
Q1 | $69.6M | Buy |
501,200
+59,614
| +13% | +$8.02M | 0.24% | 108 |
|
|
2022
Q4 | $59.9M | Sell |
441,586
-10,865
| -2% | -$1.36M | 0.23% | 116 |
|
|
2022
Q3 | $49.6M | Buy |
452,451
+133,493
| +42% | +$16.9M | 0.21% | 123 |
|
|
2022
Q2 | $42.1M | Sell |
318,958
-1,139
| -0.4% | -$149K | 0.19% | 139 |
|
|
2022
Q1 | $42.5M | Buy |
320,097
+23,933
| +8% | +$2.87M | 0.16% | 151 |
|
|
2021
Q4 | $34.5M | Buy |
296,164
+17
| +0% | +$2K | 0.13% | 175 |
|
|
2021
Q3 | $35.6M | Buy |
296,147
+50,311
| +20% | +$5.86M | 0.15% | 157 |
|
|
2021
Q2 | $29.5M | Buy |
245,836
+36,385
| +17% | +$3.99M | 0.14% | 175 |
|
|
2021
Q1 | $20.8M | Buy |
209,451
+28,141
| +16% | +$2.83M | 0.11% | 219 |
|
|
2020
Q4 | $18.1M | Sell |
181,310
-3,870
| -2% | -$410K | 0.1% | 223 |
|
|
2020
Q3 | $20.3M | Sell |
185,180
-9,749
| -5% | -$1.08M | 0.13% | 188 |
|
|
2020
Q2 | $20.6M | Sell |
194,929
-513
| -0.3% | -$53K | 0.14% | 181 |
|
|
2020
Q1 | $17.5M | Sell |
195,442
-8,985
| -4% | -$846K | 0.14% | 164 |
|
|
2019
Q4 | $20.4M | Sell |
204,427
-38,716
| -16% | -$3.64M | 0.14% | 174 |
|
|
2019
Q3 | $21.7M | Sell |
243,143
-65,107
| -21% | -$5.65M | 0.17% | 145 |
|
|
2019
Q2 | $25.4M | Buy |
308,250
+4,495
| +1% | +$352K | 0.21% | 110 |
|
|
2019
Q1 | $24.6M | Sell |
303,755
-5,668
| -2% | -$447K | 0.22% | 101 |
|
|
2018
Q4 | $23.5M | Buy |
309,423
+19,124
| +7% | +$1.49M | 0.23% | 92 |
|
|
2018
Q3 | $23M | Buy |
290,299
+4,035
| +1% | +$305K | 0.2% | 101 |
|
|
2018
Q2 | $20.1M | Buy |
286,264
+2,467
| +0.9% | +$177K | 0.19% | 113 |
|
|
2018
Q1 | $19.8M | Buy |
283,797
+12,577
| +5% | +$871K | 0.2% | 107 |
|
|
2017
Q4 | $18.8M | Buy |
271,220
+13,586
| +5% | +$916K | 0.19% | 110 |
|
|
2017
Q3 | $17.5M | Buy |
257,634
+12,392
| +5% | +$783K | 0.18% | 121 |
|
|
2017
Q2 | $16.7M | Buy |
245,242
+6,683
| +3% | +$436K | 0.18% | 122 |
|
|
2017
Q1 | $14.9M | Buy |
238,559
+22,952
| +11% | +$1.34M | 0.16% | 146 |
|
|
2016
Q4 | $11.8M | Sell |
215,607
-9,989
| -4% | -$567K | 0.14% | 177 |
|
|
2016
Q3 | $14.8M | Buy |
225,596
+5,162
| +2% | +$337K | 0.19% | 124 |
|
|
2016
Q2 | $13.3M | Buy |
220,434
+92,544
| +72% | +$5.38M | 0.18% | 138 |
|
|
2016
Q1 | $7.2M | Sell |
127,890
-12,255
| -9% | -$736K | 0.11% | 227 |
|
|
2015
Q4 | $9.52M | Buy |
140,145
+28,479
| +26% | +$1.87M | 0.16% | 161 |
|
|
2015
Q3 | $7.11M | Buy |
111,666
+12,418
| +13% | +$817K | 0.12% | 216 |
|
|
2015
Q2 | $3.16M | Buy |
99,248
+4,160
| +4% | +$285K | 0.05% | 483 |
|
|
2015
Q1 | $6.51M | Buy |
95,088
+41,164
| +76% | +$2.86M | 0.11% | 261 |
|
|
2014
Q4 | $3.79M | Buy |
53,924
+8,038
| +18% | +$576K | 0.07% | 424 |
|
|
2014
Q3 | $3.28M | Sell |
45,886
-11,430
| -20% | -$837K | 0.07% | 447 |
|
|
2014
Q2 | $4.26M | Sell |
57,316
-17,129
| -23% | -$1.24M | 0.06% | 482 |
|
|
2014
Q1 | $4.83M | Buy |
74,445
+3,472
| +5% | +$224K | 0.07% | 422 |
|
|
2013
Q4 | $4.21M | Buy |
70,973
+46,064
| +185% | +$2.5M | 0.07% | 434 |
|
|
2013
Q3 | $1.29M | Buy |
24,909
+3,588
| +17% | +$180K | 0.02% | 635 |
|
|
2013
Q2 | $1.01M | Buy |
+21,321
| New | +$1.09M | 0.02% | 665 |
|
Other funds holding AZN
EP
IA
Natixis Advisors's AZN Position: Q2 2026 in Review
Natixis Advisors increased its AstraZeneca (AZN) stake by 51% in Q2 2026, buying an estimated $125M and bringing the position to 1,978,508 shares worth $375M. The position accounts for 0.42% of the portfolio, ranked #43.
Natixis Advisors first reported a position in AZN in Q2 2013 and has held it in 53 quarters since. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- Natixis Advisors held 1,978,508 shares of AstraZeneca worth $375M as of Q2 2026.
- Natixis Advisors bought 666,009 AstraZeneca shares in Q2 2026, an estimated $125M.
- AstraZeneca made up 0.42% of Natixis Advisors's portfolio in Q2 2026, its #43 holding.
- Natixis Advisors first reported a position in AstraZeneca in Q2 2013 and has held it in 53 quarters since.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on Natixis Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.